CENTER FOR DRUG EVALUATION AND RESEARCH

APPROVAL PACKAGE FOR:

APPLICATION NUMBER

21-594

Clinical Pharmacology and Biopharmaceutics Review

OFFICE OF CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS REVIEW

NDA: 21-594	Submission Date(s): 10/31/02
Brand Name	Not applicable
Generic Name	Amiodarone hydrochloride injection
Reviewer	B. Nhi Nguyen, Pharm.D.
Team Leader	Patrick Marroum, Ph.D.
OCPB Division	One
ORM division	Cardio-renal
Sponsor	International Medication Systems, Ltd. (IMS)
Submission Type; Code	000
Formulation; Strength(s)	50 mg/mL in a Dilute-A-Jet® Additive syringe delivery system 3 mL (150 mg) and 18 mL (900 mg) vials
Indication	Initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy

1 EXECUTIVE SUMMARY

Amiodarone Hydrochloride (HCl), Cordarone IV® is approved for the initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation and for hemodynamically unstable ventricular tachycardia in patients refractory to other therapy. Wyeth Ayerst manufactures Cordarone IV®. Cordarone® is available in 3mL ampules. Each ampule contains 50 mg/mL.

International Medication Systems, Ltd. submitted an original NDA under 505(b)(2), without clinical trial data, for amiodarone hydrochloride injection, 50 mg/mL in the Dilute-A-Jet® Additive syringe delivery system. The basis for a new drug application instead of a generic drug application is that the product is being provided in a prefilled syringe. The injection is identical to the currently approved amiodarone product (Cordarone®).

Table 1. Composition of Amiodarone HCl

Amiodarone HCl injection	50 mg/mL
Amiodarone Hydrochloride	50 mg/mL
Polysorbate 80	100 mg/mL
Benzyl alcohol NF	20.2 mg/mL
Water for injection, USP	Qs to 1 mL

According to CFR 320.22 (b)(1), the in vivo bioavailability of IMS' product is self-evident and the sponsor does not have to prove in a human bioavailability study that their product is bioequivalent to Cordarone®. The reasons for the biowaiver are:

- the parenteral solution is intended solely for administration by injection
- the solution contains the same active and inactive ingredients in the same concentration as Cordarone IV®

The contents of IMS' amiodarone label are similar to Wyeth Ayerst's, except for the difference in how IMS' product will be available.

1.1 Recommendation

The Office of Clinical Pharmacology and Biopharmaceutics grants a biowaiver for amiodarone hydrochloride 50 mg/mL in a Dilute-A-Jet® Additive syringe. The application is approvable.

There are no labeling recommendations.

S

B. Nhi Nguyen, Pharm.D.
Division of Pharmaceutical Evaluation I

FT Initialed by Patrick Marroum, Ph.D.
CC list: HFD-110: NDA 21-594; HFD-860: (Nguyen, Mehta, Sahajwalla); CDER Central Document Room

16 pages redacted from this section of the approval package consisted of draft labeling

---

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Nhi Nguyen
4/18/03 01:28:25 PM
BIOPHARMACEUTICS

Patrick Marroum
4/18/03 02:49:58 PM
BIOPHARMACEUTICS